11th International Workshop on Waldenstrom's Macroglobulinemia
Attend the world’s most comprehensive hematology/oncology event on Waldenstrom’s macroglobulinemia; the 11th International Workshop on Waldenstrom’s macroglobulinemia (IWWM-11).
The 11th International Workshop for Waldenstrom's Macroglobulinemia is being held October 27th through the 30th, 2022 in Madrid, Spain. The venue chosen for this meeting is one of Madrid’s premier hotels, Westin Palace Madrid, situated in the Las Letras quarter. The hotel nestles in one of the city’s most historic areas linking the city’s most enriching museums, Prado, Reina Sofia and Thyssen-Bornemisza, vibrant parks and gardens, and epicurean eateries. Onsite registration and check-in begin at 14:00 (2:00pm) on Wednesday, October 26th, conference sessions starting on Thursday, the 27th, at 8:00am.
The Workshop’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic system, by promoting targeted research, clinical care methods, education, training, and advocacy for Waldenstrom’s macroglobulinemia.
IWWM-11 will continue to support future research by including a Junior Investigator Poster presentation event with short oral presentations. Abstract submissions for poster presentations will begin in June 2022.
Read more: 11th International Workshop on Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia Clinic
The Waldenstrom's Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Basic Research
Waldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...
Latest Bing Center News
27th Annual IWMF Virtual Educational Forum, August 27-28, 2022
The 27th Annual IWMF Educational Forum provides a unique opportunity to learn and connect with and from one another. The 2022 Virtual Ed Forum brings WM specialists, clinicians, researchers, patients, and caregivers together. A two-day program features pertinent and timely information related to symptoms and complications of WM, current treatment options, new therapies, and life topics that align with this year’s Ed Forum theme: Living, Learning, and Thriving with WM. This year’s Educational Forum will conclude with our popular “Ask the Doctors” question-and-answer session.
“Grand Rounds” with Dr. Steven Treon
A project that has been a long time in the making came to fruition earlier this year. The goal of the WMFC was to have a series of video conferences led by key WM researchers, and to specifically invite Canadian Medical Professionals to learn more about our disease from those who know it best.
When to Wait and When to Treat - Shayna Sarosiek, MD
Rare Cancers Updates offers a dynamic half-day online learning experience aimed at helping clinicians efficiently gain valuable education on a rare topic. You'll have the opportunity to earn CME credits and compete for amazing prizes during our 2022 Contest! Join us during the June 17th meeting, where you'll gain insights and practical guidance on Waldenström Macroglobulinemia. Registration is free!
Young WM International Support Group Meeting Monday, May 16th at 7:15PM U.S. ET
WM patients and caregivers under the age of 50:Join the Young WM International Support Group on May 16th with special guest, Dr. Shayna Sarosiek!
Waldenstrom’s Macroglobulinemia (WM): Treatment Progress Workshop
Workshop Date and Time: Wednesday, May 25, 2022, 1:30 – 2:30 pm, Eastern Time. Registrants can listen in live over the phone or online as a webcast. Click below to learn more or register for this workshop.
IWMF Torch April, 2022 - Bing Neel Syndrome, Dr. Jorge Castillo
In this issue of the IWMF Torch, Dr. Jorge Castillo reviews the disgnosis, indications to treat, and treatment options for Bing Neel Syndrome (BNS) in patients with WM, as these have a direct impact on further understanding the choices available to manage BNS.
Covid Antibodies, CAR-T & More. Can We Feel Hopeful this Spring?
Our IWMF Support Group Leaders and International Affiliates had the pleasure of meeting with Dr. Shayna Sarosiek of Dana-Farber Cancer Institute this week. Dr. Sarosiek covered many topics, including Evusheld, CAR-T therapy, and WM treatments on the horizon. This is a fabulous and timely presentation you don't want to miss!
Waldenström Macroglobulinemia Treatment Decisions: What’s Right for You?
When faced with a WM diagnosis, what determines the best treatment for YOU? In this 30-minute webinar, Dr. Jorge Castillo will review key factors that affect treatment decisions, emerging treatment research, and tips for partnering with your healthcare team.
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Treatment Regimens
Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies.
Living Well with Waldenstrom's Macroglobulinemia (FREE WEBINAR)
This program is designed to provide attendees with essential information that will help you participate more actively and confidently in decisions about your Waldenström Macroglobulinemia treatment and survivorship.